Pharmaceutical Singapore-based Menarini Asia-Pacific Holdings and Japanese pharma major Daiichi Sankyo (TYO: 4568) have signed a multi-year exclusive licensing agreement for the former to assume the sales, marketing and distribution of the oral, once-daily, direct factor Xa inhibitor anticoagulant Lixiana (edoxaban) in the Philippines, Malaysia and Singapore, following respective regulatory approvals in those countries. 29 June 2018